A222004 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

Study Number: A222004 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

Please Note:

This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.

Available Sites

• Missouri Baptist Medical Center

Contact Person(s)

• Monica Russo 314-996-5868

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.